Literature DB >> 1067027

Sarcoidosis of the upper respiratory tract and its relation to lupus pernio.

E Neville, R G Mills, D G James.   

Abstract

The authors present a personally studied series of 32 patients with sarcoidosis affecting the upper respiratory tract and nose. Twenty-five of these patients had lupus pernio (LP), which in 8 instances was accompanied by sarcoidosis of the upper respiratory tract (SURT). The 7 other patients had SURT (mucosal disease) without LP. There was a female to male ratio of 7:1. SURT presented mainly in the third decade, whereas LP presented mainly in the fourth and fifth. Despite this, SURT was as much a chronic manifestation of sarcoidosis as LP. Five of 11 patients (45%) presenting with SURT progressed to LP within 2 yr. Overall 26 patients (81%) had intrathoracic sarcoidosis, 19 patients (59%) had skin lesions other than LP, 10 patients (31%) had bone sarcoidosis, 7 patients (22%) had ocular lesions, and 6 patients (19%) had peripheral lymphadenopathy. The Kveim-Siltzbach skin-test was positive in 12 of 12 patients with SURT, making it a useful aid in the differential diagnosis of sarcoid granulomas in the nose. Two patients had nasal perforations, both of which followed a submucous resection.

Entities:  

Mesh:

Year:  1976        PMID: 1067027     DOI: 10.1111/j.1749-6632.1976.tb47053.x

Source DB:  PubMed          Journal:  Ann N Y Acad Sci        ISSN: 0077-8923            Impact factor:   5.691


  3 in total

1.  Case report 306. Diagnosis: sarcoidosis affecting the frontal and nasal bones.

Authors:  P Madoule; A Ellrodt; A Chevrot; D Molle; D Doyan
Journal:  Skeletal Radiol       Date:  1985       Impact factor: 2.199

Review 2.  Sarcoidosis and Its Dermatological Manifestations: A Narrative Review.

Authors:  Jancy Koneti; Swathi Priya Cherukuri; Sai Gadde; Revanth Kalluru; Rahul Chikatimalla; Thejaswi Dasaradhan
Journal:  Cureus       Date:  2022-08-16

3.  Sarcoidosis: an expanding ophthalmic horizon.

Authors:  P Henkind
Journal:  J R Soc Med       Date:  1982-03       Impact factor: 18.000

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.